Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$27.07 USD
+0.05 (0.19%)
Updated Mar 28, 2024 12:50 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Intellia Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 36 | 52 | 33 | 58 | 43 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 36 | 52 | 33 | 58 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 552 | 510 | 301 | 195 | 149 |
Income After Depreciation & Amortization | -515 | -458 | -268 | -137 | -106 |
Non-Operating Income | 34 | -16 | 0 | 2 | 7 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -481 | -474 | -268 | -134 | -100 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -481 | -474 | -268 | -134 | -100 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -481 | -474 | -268 | -134 | -100 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -506 | -451 | -261 | -130 | -101 |
Depreciation & Amortization (Cash Flow) | 9 | 8 | 7 | 6 | 6 |
Income After Depreciation & Amortization | -515 | -458 | -268 | -137 | -106 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 88.87 | 76.97 | 70.89 | 55.99 | 47.25 |
Diluted EPS Before Non-Recurring Items | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 |
Diluted Net EPS (GAAP) | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 |
Fiscal Year end for Intellia Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | -1.92 | 11.99 | 13.59 | 12.61 | 13.57 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -1.92 | 11.99 | 13.59 | 12.61 | 13.57 |
SG&A, R&D, and Dept/Amort Expenses | 137.97 | 143.10 | 145.93 | 124.57 | 123.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | -139.89 | -131.11 | -132.34 | -111.96 | -110.09 |
Non-Operating Income | 7.73 | 8.88 | 8.65 | 8.83 | -3.32 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -132.16 | -122.22 | -123.68 | -103.13 | -113.41 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -132.16 | -122.22 | -123.68 | -103.13 | -113.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -132.16 | -122.22 | -123.68 | -103.13 | -113.41 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 90.46 | 88.65 | 88.19 | 87.77 | 81.22 |
Diluted EPS Before Non-Recurring Items | -1.46 | -1.38 | -1.40 | -1.17 | -1.40 |
Diluted Net EPS (GAAP) | -1.47 | -1.38 | -1.40 | -1.17 | -1.38 |